(Q44893142)

7 December 2017

0 references

High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma (English)

1 reference

7 December 2017

0 references

1 reference

3

Beate Kempf-Bielack

0 references

author name string

Brigitte C Widemann

1

1 reference

7 December 2017

Frank M Balis

2

1 reference

7 December 2017

Beate Kempf-Bielack

3

1 reference

7 December 2017

Stefan Bielack

4

1 reference

7 December 2017

Charles B Pratt

5

1 reference

7 December 2017

Stefano Ferrari

6

1 reference

7 December 2017

Gaetano Bacci

7

1 reference

7 December 2017

Alan W Craft

8

1 reference

7 December 2017

Peter C Adamson

9

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

7 December 2017

1 reference

7 December 2017

100

1 reference

7 December 2017

2222-2232

1 reference

7 December 2017

10

1 reference

Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate

7 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

Hemodialysis and enzymatic cleavage of methotrexate in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

Methotrexate and hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

Experience of the EORTC Radiotherapy/Chemotherapy Group in osteosarcoma trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

The treatment of localized osteosarcoma of the extremities: the Italian experience. Studies of the National Research Council

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

Hemoperfusion for methotrexate removal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

Removal of methotrexate by continuous venovenous hemodiafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

The treatment of osteosarcoma: present trends. The Scandinavian Sarcoma Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

High-dose methotrexate: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Methotrexate: clinical pharmacology, current status and therapeutic guidelines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Severe renal toxicity due to intermediate-dose methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Toxicity associated with combination chemotherapy for osteosarcoma: A report of the cooperative osteosarcoma study (COSS 80)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Clinical use of thymidine as a rescue agent from methotrexate toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

[Severe renal impairment of methotrexate elimination after high dose therapy]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Severe complications after high-dose methotrexate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

High-dose leucovorin as sole therapy for methotrexate toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Charcoal haemoperfusion and methotrexate toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Effective clearance of methotrexate using high-flux hemodialysis membranes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Results of the COSS-77 and COSS-80 studies on adjuvant chemotherapy in osteosarcoma of the extremities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Neoadjuvant chemotherapy of osteosarcoma. Preliminary results of the cooperative COSS-86 osteosarcoma study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Osteosarcoma of the trunk treated by multimodal therapy: experience of the Cooperative Osteosarcoma study group (COSS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Primary chemotherapy and delayed surgery for non-metastatic telangiectatic osteosarcoma of the extremities. Results in 28 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Effective removal of methotrexate by high-flux hemodialysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Continuous plasma resin perfusion for detoxification of methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Extremity and non-extremity high-grade osteosarcoma -- the Norwegian Radium Hospital experience during the modern chemotherapy era

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Renal toxicity with cumulative doses of cis-diamminedichloroplatinum-II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Removal of methotrexate by hemodiafiltration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Successful rescue in a patient with high dose methotrexate-induced nephrotoxicity and acute renal failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Charcoal hemoperfusion and methotrexate toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxicity: nonrenal excretion of serum methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Acute renal failure after high-dose methotrexate therapy. Role of hemodialysis and plasma exchange in methotrexate removal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20255

7 January 2021

Identifiers

DOI

10.1002/CNCR.20255

1 reference

7 December 2017

1 reference